Aclarion (ACON) investor relations material

Executive summary

• Revenue increased 65.6% year-over-year to $75,730, driven by higher NOCISCAN report volumes in the UK following local coverage decisions.

• Net loss widened to $7.2 million from $7.0 million in 2024, reflecting increased investments in sales, marketing, and R&D.

• Cash and cash equivalents at year-end were $12.0 million, with additional $10.4 million raised in January 2026, expected to fund operations into Q1 2028.

• The company completed multiple equity and warrant offerings, retired all outstanding debt, and redeemed all Series B Preferred Stock.

Financial highlights

• Revenue: $75,730 (+65.6% YoY); Cost of revenue: $68,902 (-18.6% YoY); Gross profit: $6,828.

• Operating expenses: Sales & marketing $1.9M (+94.6%), R&D $1.0M (+16.3%), G&A $4.1M (+14.3%).

• Net loss: $7,233,629 (vs. $6,992,927 in 2024); Loss per share: $(13.61).

• Interest income rose to $411,061 from $318, reflecting higher cash balances.

• Penalties and settlements expense increased to $672,625 due to a $687,500 settlement.

Outlook and guidance

• Management expects continued revenue growth as scan volumes and payer coverage expand.

• Ongoing investments in clinical trials (CLARITY Trial), sales, and marketing are expected to increase expenses.

• Current cash position is projected to fund operations through Q1 2028; additional capital may be needed for further growth.